DETERMINING MORTALITYVALUABLE OFCYTOKINE STORM SCORE (CSs) IN COVID – 19 PATIENTS TREATMENTED IN MILITARY HOSPITAL 175
DOI:
https://doi.org/10.59354/ydth175.2022.55Keywords:
COVID – 19, CSs, cytokine storm score, mortality prognosisAbstract
Objective: Determine prognostic value of Cytokine Storm Score (CSs) in hospitalized COVID-19 patients.
Materials and Methods: Prospective study, longitudinal follow-up of 81 COVID-19 patients admitted to the COVID-19 treatment center, Military Hospital 175 from August 2021 to October 2021. CSs and CURB - 65 score were used to assess the risk of death when patients are hospitalized for treatment.
Results:81 COVID-19 patients were studied, the mean age was 55.67 ± 14.6. Male patients were 45.7% and female patients were54.3%. There were 44 CSs positive patients, accounting for 54.32%. The higher the conventional CSs score in the more severe COVID-19 patients, the statistically significant difference, p< 0.001. The conventional CSs scale has a good predictive ability of mortality in COVID-19 patients, with an area under the ROC curve of 0.95. The cut-off point with the best predictive value for mortality is CSs ≥ 4 points, with sensitivity 96.55%, specificity 82.69%, positive predictive value 75.67%, negative predictive value 97.72%.
Conclusion: The conventional CSs is an effective tool to predict the risk of death for hospitalized COVID-19 patients.
References
Bộ y tế, Hướng dẫn chẩn đoán và điều trị COVID-19 do chủng vi rút Corona mới (SARS-CoV-2) theo Quyết định 3416/QĐ-BYT ngày 14/7/2021
Bộ y tế Cổng thông tin của Bộ Y tế về đại dịch Covid-19 - covid19.gov. vn.
Cappanera S., et al. (2021), “When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It”, J Clin Med, 10(2).
Fine M. J., et al. (1997), “A prediction rule to identify low-risk patients with community-acquired pneumonia”, N Engl J Med, 336(4), 243-50.
Guo J., et al. (2020), “CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study”, Epidemiol Infect, 148, e241.
Lim W. S., et al. (2003), “Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study”, Thorax, 58(5), 377-82.
Schiffrin E. L., et al. (2020), “Hypertension and COVID-19”, Am J Hypertens, 33(5), 373-374.
Singanayagam A., Chalmers J. D. (2013), “Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia”, Lancet Respir Med, 1(8), 653-662.
Yang X., et al. (2020), “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study”, Lancet Respir Med, 8(5), 475-481.
Zhou F., et al. (2020), “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”, Lancet, 395(10229), 1054-1062.
